Lavipharm (Greece) Buy Hold or Sell Recommendation
| LAVI Stock | EUR 0.81 0.02 2.53% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Lavipharm SA is 'Strong Sell'. Macroaxis provides Lavipharm buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LAVI positions. The advice algorithm takes into account all of Lavipharm's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Lavipharm's buy or sell advice are summarized below:
Real Value 0.7 | Hype Value 0.81 | Market Value 0.81 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Lavipharm SA given historical horizon and risk tolerance towards Lavipharm. When Macroaxis issues a 'buy' or 'sell' recommendation for Lavipharm SA, the advice is generated through an automated system that utilizes algorithms and statistical models.
Lavipharm |
Execute Lavipharm Buy or Sell Advice
The Lavipharm recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lavipharm SA. Macroaxis does not own or have any residual interests in Lavipharm SA or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lavipharm's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Lavipharm Trading Alerts and Improvement Suggestions
| Lavipharm SA has some characteristics of a very speculative penny stock | |
| Lavipharm SA has high likelihood to experience some financial distress in the next 2 years | |
| About 67.0% of the company outstanding shares are owned by corporate insiders |
Lavipharm Returns Distribution Density
The distribution of Lavipharm's historical returns is an attempt to chart the uncertainty of Lavipharm's future price movements. The chart of the probability distribution of Lavipharm daily returns describes the distribution of returns around its average expected value. We use Lavipharm SA price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lavipharm returns is essential to provide solid investment advice for Lavipharm.
| Mean Return | 0.05 | Value At Risk | -3.49 | Potential Upside | 4.49 | Standard Deviation | 2.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lavipharm historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lavipharm Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lavipharm or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lavipharm's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lavipharm stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.03 | |
β | Beta against NYSE Composite | 0.16 | |
σ | Overall volatility | 2.40 | |
Ir | Information ratio | -0.0096 |
Lavipharm Volatility Alert
Lavipharm SA currently demonstrates below-average downside deviation. It has Information Ratio of -0.01 and Jensen Alpha of 0.03. Lavipharm SA is a potential penny stock. Although Lavipharm may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Lavipharm SA. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Lavipharm instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Lavipharm Fundamentals Vs Peers
Comparing Lavipharm's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lavipharm's direct or indirect competition across all of the common fundamentals between Lavipharm and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lavipharm or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lavipharm's fundamental indicators could also be used in its relative valuation, which is a method of valuing Lavipharm by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lavipharm to competition |
| Fundamentals | Lavipharm | Peer Average |
| Return On Asset | 0.0403 | -0.14 |
| Profit Margin | 0.02 % | (1.27) % |
| Operating Margin | 0.08 % | (5.51) % |
| Current Valuation | 59.98 M | 16.62 B |
| Shares Outstanding | 18.29 M | 571.82 M |
| Shares Owned By Insiders | 67.47 % | 10.09 % |
| Price To Earning | 12.42 X | 28.72 X |
| Price To Sales | 0.17 X | 11.42 X |
| Revenue | 41.37 M | 9.43 B |
| Gross Profit | 15.89 M | 27.38 B |
| EBITDA | 4.72 M | 3.9 B |
| Net Income | 1.72 M | 570.98 M |
| Cash And Equivalents | 1.85 M | 2.7 B |
| Cash Per Share | 0.04 X | 5.01 X |
| Total Debt | 40.54 M | 5.32 B |
| Current Ratio | 1.29 X | 2.16 X |
| Book Value Per Share | (0.47) X | 1.93 K |
| Cash Flow From Operations | 3.82 M | 971.22 M |
| Earnings Per Share | 0.04 X | 3.12 X |
| Number Of Employees | 5 | 18.84 K |
| Beta | 0.66 | -0.15 |
| Market Capitalization | 8.56 M | 19.03 B |
| Total Asset | 82 M | 29.47 B |
| Retained Earnings | (181 M) | 9.33 B |
| Working Capital | (66 M) | 1.48 B |
| Current Asset | 21 M | 9.34 B |
| Current Liabilities | 87 M | 7.9 B |
| Z Score | -2.8 | 8.72 |
| Five Year Return | 4.13 % |
Lavipharm Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lavipharm . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Lavipharm Buy or Sell Advice
When is the right time to buy or sell Lavipharm SA? Buying financial instruments such as Lavipharm Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lavipharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Lavipharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Lavipharm Stock analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |